Imaging Science Laboratory, Department of Radiology, Mount Sinai School of Medicine, New York, NY 10029, USA.
J Am Coll Cardiol. 2012 Feb 7;59(6):616-26. doi: 10.1016/j.jacc.2011.10.881.
This study sought to evaluate the in vivo magnetic resonance imaging (MRI) efficacy of manganese [Mn(II)] molecular imaging probes targeted to oxidation-specific epitopes (OSE).
OSE are critical in the initiation, progression, and destabilization of atherosclerotic plaques. Gadolinium [Gd(III)]-based MRI agents can be associated with systemic toxicity. Mn is an endogenous, biocompatible, paramagnetic metal ion that has poor MR efficacy when chelated, but strong efficacy when released within cells.
Multimodal Mn micelles were generated to contain rhodamine for confocal microscopy and conjugated with either the murine monoclonal IgG antibody MDA2 targeted to malondialdehyde (MDA)-lysine epitopes or the human single-chain Fv antibody fragment IK17 targeted to MDA-like epitopes ("targeted micelles"). Micelle formulations were characterized in vitro and in vivo, and their MR efficacy (9.4-T) evaluated in apolipoprotein-deficient (apoE(-/-)) and low-density lipoprotein receptor negative (LDLR(-/-)) mice (0.05 mmol Mn/kg dose) (total of 120 mice for all experiments). In vivo competitive inhibition studies were performed to evaluate target specificity. Untargeted, MDA2-Gd, and IK17-Gd micelles (0.075 mmol Gd/kg) were included as controls.
In vitro studies demonstrated that targeted Mn micelles accumulate in macrophages when pre-exposed to MDA-LDL with ∼10× increase in longitudinal relativity. Following intravenous injection, strong MR signal enhancement was observed 48 to 72 h after administration of targeted Mn micelles, with colocalization within intraplaque macrophages. Co-injection of free MDA2 with the MDA2-Mn micelles resulted in full suppression of MR signal in the arterial wall, confirming target specificity. Similar MR efficacy was noted in apoE(-/-) and LDLR(-/-) mice with aortic atherosclerosis. No significant differences in MR efficacy were noted between targeted Mn and Gd micelles.
This study demonstrates that biocompatible multimodal Mn-based molecular imaging probes detect OSE within atherosclerotic plaques and may facilitate clinical translation of noninvasive imaging of human atherosclerosis.
本研究旨在评估针对氧化特异性表位(OSE)的锰[Mn(II)]分子成像探针的体内磁共振成像(MRI)效果。
OSE 在动脉粥样硬化斑块的起始、进展和不稳定中起关键作用。钆[Gd(III)]基 MRI 造影剂可能与全身毒性有关。Mn 是一种内源性、生物相容性、顺磁性金属离子,当其螯合时 MRI 效果较差,但在细胞内释放时效果较强。
制备了包含罗丹明的多模态 Mn 胶束,用于共聚焦显微镜,并与针对丙二醛(MDA)-赖氨酸表位的鼠单克隆 IgG 抗体 MDA2 或针对 MDA 样表位的人单链 Fv 抗体片段 IK17 (“靶向胶束”)偶联。对胶束制剂进行了体外和体内表征,并在载脂蛋白缺陷(apoE(-/-))和低密度脂蛋白受体阴性(LDLR(-/-))小鼠(0.05mmol Mn/kg 剂量)中评估其 MRI 效果(共 120 只小鼠进行所有实验)。进行了体内竞争性抑制研究以评估靶特异性。非靶向、MDA2-Gd 和 IK17-Gd 胶束(0.075mmol Gd/kg)作为对照。
体外研究表明,当预先暴露于 MDA-LDL 时,靶向 Mn 胶束在巨噬细胞中积累,纵向相关性增加约 10 倍。静脉注射后,在给予靶向 Mn 胶束后 48 至 72 小时观察到强烈的 MRI 信号增强,并与斑块内巨噬细胞内的信号增强相一致。用游离 MDA2 与 MDA2-Mn 胶束共注射导致动脉壁中的 MRI 信号完全抑制,证实了靶特异性。在载脂蛋白缺陷(apoE(-/-))和低密度脂蛋白受体阴性(LDLR(-/-))的小鼠中,主动脉粥样硬化也具有相似的 MRI 效果。靶向 Mn 和 Gd 胶束之间的 MRI 效果无显著差异。
本研究表明,生物相容性的多模态 Mn 基分子成像探针可检测动脉粥样硬化斑块中的 OSE,并可能促进非侵入性成像人类动脉粥样硬化的临床转化。